Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
Yong-Xian ShaoCui-Li LiangYa-Ying SuYun-Ting LinZhi-Kun LuRui-Zhu LinZhi-Zi ZhouChun-Hua ZengChun-Yan TaoZong-Cai LiuWen ZhangLi LiuPublished in: Orphanet journal of rare diseases (2024)
Empagliflozin treatment for pediatric GSD Ib patients is efficient and safe. Increase of urine glucose is a signal for pharmaceutical effect, however attention to urinary infection and hypoglycemia is suggested.